EA202192867A1 - Составы с пролонгированным высвобождением - Google Patents

Составы с пролонгированным высвобождением

Info

Publication number
EA202192867A1
EA202192867A1 EA202192867A EA202192867A EA202192867A1 EA 202192867 A1 EA202192867 A1 EA 202192867A1 EA 202192867 A EA202192867 A EA 202192867A EA 202192867 A EA202192867 A EA 202192867A EA 202192867 A1 EA202192867 A1 EA 202192867A1
Authority
EA
Eurasian Patent Office
Prior art keywords
extended release
release formulations
relates
compositions
tyrosine
Prior art date
Application number
EA202192867A
Other languages
English (en)
Inventor
Стивен Хоффман
Джон Ротман
Original Assignee
ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи filed Critical ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи
Publication of EA202192867A1 publication Critical patent/EA202192867A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)

Abstract

Изобретение относится к композициям с ингибитором тирозингидроксилазы и способам для таких композиций. Конкретно, изобретение относится к составу с пролонгированным высвобождением ингибитора тирозингидроксилазы, в частности -метил-пара-тирозина.
EA202192867A 2019-04-19 2020-04-17 Составы с пролонгированным высвобождением EA202192867A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836256P 2019-04-19 2019-04-19
PCT/US2020/028624 WO2020214879A1 (en) 2019-04-19 2020-04-17 Sustained release formulations

Publications (1)

Publication Number Publication Date
EA202192867A1 true EA202192867A1 (ru) 2022-01-20

Family

ID=72837927

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192867A EA202192867A1 (ru) 2019-04-19 2020-04-17 Составы с пролонгированным высвобождением

Country Status (7)

Country Link
US (1) US20220211650A1 (ru)
EP (1) EP3955910A4 (ru)
JP (1) JP2022529189A (ru)
CN (1) CN114901272A (ru)
AU (1) AU2020257406A1 (ru)
EA (1) EA202192867A1 (ru)
WO (1) WO2020214879A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US20220288000A1 (en) * 2021-03-09 2022-09-15 Hoffman Technologies Llc Chewable formulations
WO2024059323A1 (en) * 2022-09-16 2024-03-21 Halas Francis Peter Low dose, sustained release formulation for alleviating symptoms caused by increased levels of dopamine and norepinephrine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057317A (en) * 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
JP5048177B2 (ja) * 1998-05-15 2012-10-17 中外製薬株式会社 放出制御製剤
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US20040228872A1 (en) * 2003-02-21 2004-11-18 Philip Hallinger Bonner Tyrosine kinase inhibitors as an adjunctive therapy to botulinum toxin treatment
ITFI20050215A1 (it) * 2005-10-13 2007-04-14 Valpharma Internat S P A Composizione nutrizionale a base di amminoacidi
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
WO2011047412A1 (en) * 2009-10-22 2011-04-28 The Heart Research Institute Ltd Tyrosine and l-dopa for reducing l-dopa incorporation into proteins
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
RU2545734C1 (ru) * 2014-01-31 2015-04-10 Открытое акционерное общество "Всероссийский Научный Центр Молекулярной Диагностики и Лечения" (ОАО "ВНЦМДЛ) Лекарственный препарат для лечения болезни паркинсона
GB201419257D0 (en) * 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
CN111032089A (zh) * 2017-07-19 2020-04-17 霍夫曼技术公司 用于治疗应激相关障碍的组合物

Also Published As

Publication number Publication date
JP2022529189A (ja) 2022-06-17
CN114901272A (zh) 2022-08-12
AU2020257406A1 (en) 2021-12-16
EP3955910A1 (en) 2022-02-23
WO2020214879A1 (en) 2020-10-22
US20220211650A1 (en) 2022-07-07
EP3955910A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
EA202192867A1 (ru) Составы с пролонгированным высвобождением
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
CO2022001590A2 (es) Inhibidores de parp1
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201991799A1 (ru) Диспергируемые в воде составы
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
CL2019001993A1 (es) Inhibidores selectivos de jak1.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
EA201890638A1 (ru) Отклоняющие кислоты, содержащие водорастворимое замедляющее действие средство, а также способы изготовления и применения
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF